{"name":"Rapport Therapeutics Inc.","slug":"rapport-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOYzhIMDROUTVfZ1ROTEpraVhELWJDcW9oNnN2MGJpN1I1ejRPbF8yMnUwdUE3X2hOSXBUZGluRVJwdEVfZVp4SFZRSGpqSEpHNDRzSFFzazZUd09EQzBGcXV2TDR1em40TERERTEweGVtZ2lwSlE5TlhNN3cxOW5qbmI1RU53a05CYUlVYU5IR19LNXc5OUFQNjlSNDZhbnVIYmtTOWZCdF96TGtOQ2JJYm85Ym1vOE1wLTVrdzg3NWpndXp5X1RfaURPcjVnSGhVTXpvZWV0TjRVYUVJdmlJemM0ejA3Smp0d2R4T25XckY0Wmh3TDlYbC13WmYxZUxudDg2bnFoVFdjS0hMQjJHelR3cnYza0NOdWJoSFNjVFRUWmtXV1ZZ?oc=5","date":"2026-04-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (AN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPUFBZVjZTc0VhN29yX3ZtUGRQcDN6X0FOOEF4eTl0TFFlaTlIMVhMc2NrWmFNaHktbnpyd0pPU0ppSHZyZEM0YjFfcTI3TnhOOGFuaE93dnhERGxVWnIwNEhSbG4yZHYzemxzTzJRQ0lIZ3FKV0UzaVFRR3RoVVJJaHM3MS1UQzhsRnJuRUM2UmtOZXVNRUM5OWx1N2F3OEZndVU1ZjIzelNTODEzd1EtU3gweXRuX0IwUlNxVFBpVklFYXlYUWVFclZabXE1c1lGZXVPTGZZeTVFbE9pekxHZ1VVZk1JRjBRT25MTFZQNEptdkhPRWJYdnR1djU3UkxtbmhsLXZYaEpiY1RJdFNn?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOZWZ3YXVBeWJvU1pmaXoxQ0ZtM1JUX0FTN2pYbnFJVENLb0ZHck5TelFWT21XSTBLQ1JlN2l0Qk9zbktOaHpDa0JWakdxX1hJY2dlbWVIRFNXSDJsbDdQSHJNa2g2UGFuWklRTHlocW5FYkZFU3RERzlTSk9IZTlGNnhBZ1NFb1h2cXVfV1F3Z3I5UVpTQzhPOERsQlYxczJOeThuODBxaGNiUm5Wd0Q2Z3NCRU85cW5CdDlOVHZtdld1UG1xbDFqQjZ2cjMtcVFCb055RU9B?oc=5","date":"2026-03-10","type":"pipeline","source":"Investing.com","summary":"Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential - Investing.com","headline":"Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNaFRUWTZaQkhFODJwaVljMl84VG9qVnYzeW5MZ1RNZEM2dVU1cGFKdk1zZDYzLWFIMFcxMGM1TXRTLU50UkRacVN5QUxoZ1BJZlpTSXhNNFA4cW1EN3NuSzJfd1lmckMxYm9hQkxQVGNiT0dqekVRRGNJQTVPM1l6MzBLVzdYX1lNVVpaTWVGTWdFZ2xFVmc?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance","headline":"Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-07","type":"pipeline","source":"simplywall.st","summary":"Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st","headline":"Have Rapport Therapeutics Insiders Been Selling Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPR2JfMlo2LUthMFFESW0zOE5LWERZUTZqNmpJd2prcm9rV0FYVEliWjVXY1ZLUXhZTTg5RmF0SmxWbXVhSTgtbTRFY2VQLThsS3ltZ3pyenl0T3pJaGhma1ZoWGRFaUVYZDRnYjNqTzhyWnlKWDExY0puM2JMemdOdmUzdDBaVzlzQ1B0ZDhVNTVBcEJsM2JEYktSR2EwbVZVSVdTMExIdFF2QzlkSlRVX0gtRE9MNFdBT1diNWhKd3A3blpUOHpISnFWYldjckE5T2NQcXlDSkNIc2NjNlhnWm9Kd0ZVck4tanZQZVNPRXFJZDU0a3VHN1gzVlVnLVc4Q1YzRzVNb3g?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire","headline":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbmw2aTJBZDlsQnA4MmpYTXJpZ0tteFhPb3pleEhvWWRjaGFPQ0JZbHNvcHdwenE5c1oyY3lhNkVhV19oSzdaTlNyYXFtcVR1YWV3dnJiYXZiMkdFTHJBTFFraFdzblZVUWFtODRjbTFZRDE1Z1U5bWpqSUx2MXlncjdRY2oxaG1SSU5EN2pwMVBzMFZ3THVnQg?oc=5","date":"2025-09-08","type":"trial","source":"BioPharma Dive","summary":"Rapport shares double on better-than-expected seizure drug data - BioPharma Dive","headline":"Rapport shares double on better-than-expected seizure drug data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNb0Q5ZmtCSUt2UFptQXJ6U2s5SXctb2VLNTc0UXlyTmlYRklSTUxXakc1MWY0MDBwb2NlTnpncnlMb0E0SjN6SlNJaTdnN0Q0VDg0WUNHY0ltcFBnZkFNaURRVklHcnltQmNScmtVUVhsYXZHYU5PVWlzTVhMTjdnTm1oLWpqVWdHbWlxMg?oc=5","date":"2025-09-08","type":"regulatory","source":"Tokenist","summary":"Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket? - Tokenist","headline":"Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPbUVHQy16Y1dncXpyQXJJWEdZYnN1RXNkV1Vfam1CSkVmbkRIOWNWeFVqM3ZEb1dnTVh3YWpCSEYyYzVSU0pKc1cteXVDUl9mUmhzTXV5R1VBcXloV1dsc3d3dVJFb2FuM1JVVDhEMGVkR2x5SGVhNW1ScEY2OEtuME9Da0RieFR6TGRyNzF4UUNlLUd2cWE3QkdPRFVEalJSbzBWRVNzdXJfSzljcjhXVmw2dzV5TzJIeDZkcFp3?oc=5","date":"2025-09-05","type":"trial","source":"Stock Titan","summary":"Key Epilepsy Drug Trial Results Coming Monday: Rapport's RAP-219 Phase 2a Data Could Impact Treatment - Stock Titan","headline":"Key Epilepsy Drug Trial Results Coming Monday: Rapport's RAP-219 Phase 2a Data Could Impact Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVWZ1MkJFZktUMTZJR2R6SEVocTBaVy16SkNjMGVuUjE2MUlEek9MWkVkbEtwR2ZQaE00SmhSaFRqZEpDUTZrbTJ6ZGRNZWo1c012c3FnV2swZ2NqWnBGSEpJVHBqeDE5NXdJdXI0T3RkYmRqSzUtZ09CWjcydnlYVWZHcXZKd2RpQVRQQjVlMWx3TExlQUplQkVnUQ?oc=5","date":"2025-03-31","type":"pipeline","source":"Seeking Alpha","summary":"Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha","headline":"Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOcnNad1hERnEwSHhUWU9uQzgtSm5aYk5IOEJjWUF1bGZLNU10WHpfU2VMdW12UTJfS3U2UG5DN0twVmdJRjRIX3ZPYTFENzFzZnIyVTFtUjZIdFFKU3Z1WVJSa19NYmVZeXBxaHFrUUJxa2ZxcmE5dVB0aHRmckkyRUI3RVRMZWhhWUZCNzYxR2pLUTY1VGQxMjlfaVVyU1MtUEpZMmMtWE1JTDZFVjlIRnljUWRLX3ByckpFQVZ4YTRVaXgya3lpMXFIdnJ5M0tNRXlLdVMyaGNMYTVqcm9EeGtsaTdVZW1kVmUteEFpWGN1TTNJU1BaV0JvN0xHNW5peWFBUUlvR0ZlV2JBXzlKQVBfWU80aTZxTTk4?oc=5","date":"2025-03-04","type":"pipeline","source":"BioSpace","summary":"Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - BioSpace","headline":"Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMnd6RFc0dzlPMjUzN0FZdmhtU3YtelNqd1FmaEp0YS1Ia3NWZndwYVJxX0huZmRFTnBIUU0wZHFFVUZkQUxNNXprQWxyQXZSOEp1WkxsTmRiYm5iREFnSTFxT2Q1LXJLQkZnV2FRbGk0RE4yZjVDdU1DVmtKOEsteXNEZHJjZE8wclRFZmw3Q0tnVV8wRy1qalU4enBNbUNSVUhVTEhhMUdGRzlfaG9B?oc=5","date":"2023-10-30","type":"pipeline","source":"businesswire.com","summary":"Rapport Therapeutics Appoints Chief Financial Officer - businesswire.com","headline":"Rapport Therapeutics Appoints Chief Financial Officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}